As of January 3, 2020, the AmeriHealth Dosage and Frequency Program will expand to include 11 new drugs. Most of these medical benefit drugs are used to treat pulmonary arterial hypertension or are biosimilars to antineoplastic agents that are already part of this program.

The following is the list of new drugs that will be added to this program:

• Flolan^® (epoprostenol sodium)
• Kanjinti^TM (trastuzumab-anns)
• Krystexxa^® (pegloticase)
• Remodulin^® (treprostinil)
• Revatio^® (sildenafil)
• Ruxience^TM (rituximab-pvvr)
• Tyvaso^® (treprostinil)
• Veletri^® (epoprostenol)
• Ventavis^® (iloprost)
• Xembify^® (immune globulin subcutaneous, human-klhw)
• Zirabev^TM (bevacizumab-bvzr)

Learn more

For more information on the dosage and frequency guidelines, please refer to the medical policies for each drug in the program. To access these policies, visit our Medical Policy Portal.

The complete list of all 71 drugs on this program can be found on our websites for AmeriHealth New Jersey and AmeriHealth Pennsylvania.

If you have any questions about this program, please call the AmeriHealth Clinical Services department at 1-888-YOUR-AH1
(1-888-968-7241) for AmeriHealth New Jersey and 1-800-275-2583 for AmeriHealth Pennsylvania.